Tumor cells were labeled with the anti-CD80 antibody in 28 cases (72%), mostly myelomonocytic and monocytic/monoblastic variants (Figure 4, Table 6, Supplementary Figure S1, Supplementary Table S5). This evidence concerns the gene CD80 and neoplasm.